The anxiolytic effects of somatostatin following intra-septal and intra-amygdalar microinfusions are reversed by the selective sst2 antagonist PRL2903

► Somatostatin [SST] mediates its central functions through receptors sst1-5. ► Intra-amygdalar or intra-septal infusion of SST reduced anxiety in the plus-maze. ► PRL2903, a selective sst2 antagonist, reversed these anxiolytic effects of SST. ► These findings suggest sst2 receptors in the amygdala and septum mediate anxiety.